Entod Pharma to launch GLO division for glaucoma

Published On 2022-12-12 11:00 GMT   |   Update On 2022-12-12 11:00 GMT

New Delhi: Entod Pharmaceuticals has announced that the company is all set to launch its GLO division to further expand its business. This one-of-a-kind ophthalmic subspeciality division is focused on the treatment of the eye condition glaucoma, which is a leading cause of irreversible blindness in India. 

Earlier this year, Entod Pharmaceuticals marked its presence in two major arenas. The first was the launch of its HyTek Surgical, a super-speciality ophthalmic surgical division, catering to intra-operative solutions for ophthalmic surgical needs. The other was it's dermatological venture in collaboration with its UK sister company Entod Beauty London Ltd, under which Entod Beauty products began their sale in India.

Advertisement

Nikkhil K Masurkar, CEO, Entod Pharmaceuticals said, "This year has been both challenging and exceptional for our business where we focussed on expanding our horizon beyond the convention. We have flourished in all the spheres that we set foot in. The latest milestone being the launch of our GLO Division is envisioned with the mission to ensure some real changes to the plight of glaucoma in our country."

Advertisement

Anjula Masurkar, Clinical Director, Entod Pharmaceuticals commented, "This move is bound to further strengthen ophthalmology medicine in India. Our GLO division will include some of the best quality anti-glaucoma medicines intended for promotion across the country and that too at competitor prices for patients. Over 95% of globally available anti-glaucoma molecules and therapies shall be covered through this division thereby giving access to crores of patients across then country. Furthermore our research teams are currently engaged in investigating several new glaucoma therapeutic options, that shall provide the latest treatment advances."

The company has therapeutic solutions covering all major eye health issues along with those encompassing ENT and dermatology.

Read also: ENTOD Pharma launches dermatological venture in India

Tags:    

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News